# ONC catalysts: BeOne Medicines Ltd. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/onc/catalysts

> BeOne Medicines Ltd. (ONC) has 30 upcoming catalysts. The next is the BRUKINSA® (zanubrutinib) topline data readout, Dec 2026 to Mar 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | BeOne Medicines Ltd. |
| Ticker | ONC (Nasdaq) |
| SEC CIK | 1651308 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/onc |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 14, 2019 | [BRUKINSA® (zanubrutinib) FDA approval](https://sec-api.dev/pdufa/zanubrutinib) | ONC |  | completed, approved | "NDA213217 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20191114, review_priority PRIORITY; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213217%22)) |
| August 31, 2021 | [BRUKINSA® (zanubrutinib) label expansion decision](https://sec-api.dev/pdufa/zanubrutinib) | ONC |  | completed, approved | "NDA213217 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20210831, review_priority STANDARD; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213217%22)) |
| September 14, 2021 | [BRUKINSA® (zanubrutinib) label expansion decision](https://sec-api.dev/pdufa/zanubrutinib) | ONC |  | completed, approved | "NDA213217 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20210914, review_priority PRIORITY; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213217%22)) |
| January 19, 2023 | [BRUKINSA® (zanubrutinib) label expansion decision](https://sec-api.dev/pdufa/zanubrutinib) | ONC |  | completed, approved | "NDA213217 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20230119, review_priority STANDARD; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213217%22)) |
| December 21, 2023 | [BRUKINSA® (zanubrutinib) label expansion decision](https://sec-api.dev/pdufa/zanubrutinib) | ONC |  | completed, approved | "NDA213217 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20231221, review_priority STANDARD; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213217%22)) |
| Mar 2024 | [TEVIMBRA® (tislelizumab) FDA approval](https://sec-api.dev/pdufa/tislelizumab) | ONC |  | completed, approved | "In March 2024, we subsequently received FDA approval for TEVIMBRA for this second-line indication." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1651308/000162828026070477/bgne-20260930.htm)) |
| March 7, 2024 | [BRUKINSA® (zanubrutinib) label expansion decision](https://sec-api.dev/pdufa/zanubrutinib) | ONC |  | completed, approved | "NDA213217 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20240307, review_priority STANDARD; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213217%22)) |
| March 13, 2024 | [Tevimbra (tislelizumab-jsgr) FDA approval](https://sec-api.dev/pdufa/tislelizumab-jsgr) | ONC | To treat unresectable or metastatic esophageal squamous cell carcinoma | completed, approved | "Tevimbra \| tislelizumab-jsgr \| 3/13/2024 \| To treat unresectable or metastatic esophageal squamous cell carcinomaDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| September 26, 2024 | [Tevimbra (tislelizumab-jsgr) FDA advisory committee meeting](https://sec-api.dev/pdufa/tislelizumab-jsgr) | ONC | same proposed indication | completed | "The Committee will also discuss BLA 761417 for tislelizumab injection, submitted by BeiGene USA, Inc., for the same proposed indication." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024)) |
| November 12, 2024 | [BeOne Medicines Ltd. earnings report](https://sec-api.dev/companies/onc/catalysts) | ONC |  | completed | "BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000165130824000150/exhibit991-q32024earningsr.htm)) |
| December 26, 2024 | [Tevimbra (tislelizumab-jsgr) FDA approval](https://sec-api.dev/pdufa/tislelizumab-jsgr) | ONC |  | completed, approved | "BLA761417 ORIG-1 (Type 9 - New indication submitted as distinct BLA, consolidated): submission_status AP, submission_status_date 20241226, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761417%22)) |
| December 27, 2024 | [TEVIMBRA® (tislelizumab) FDA approval](https://sec-api.dev/pdufa/tislelizumab) | ONC |  | completed, approved | "On December 27, 2024, we announced that the U.S. Food and Drug Administration ("FDA") approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma in adults whose tumors express PD-L1 (≥1)." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1651308/000165130825000031/bgne-20241231.htm)) |
| 1H 2025 | [IMDELLTRA® (tarlatamab) topline data readout](https://sec-api.dev/pdufa/tarlatamab) | ONC |  | scheduled | "•Tarlatamab (AMG757, DLL3xCD3 BiTE): anticipate data readout from Phase 3 study in second-line small cell lung cancer in the first half of 2025;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000165130825000029/exhibit991-q42024earningsr.htm)) |
| February 27, 2025 | [BeOne Medicines Ltd. earnings report](https://sec-api.dev/companies/onc/catalysts) | ONC |  | completed | "BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000165130825000029/exhibit991-q42024earningsr.htm)) |
| March 3, 2025 | [Tevimbra (tislelizumab-jsgr) FDA approval](https://sec-api.dev/pdufa/tislelizumab-jsgr) | ONC |  | completed, approved | "BLA761380 ORIG-1 (Type 9 - New indication submitted as distinct BLA, consolidated): submission_status AP, submission_status_date 20250303, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (islelizumab-jsgr)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761380%22)) |
| March 4, 2025 | [TEVIMBRA® (tislelizumab) FDA approval](https://sec-api.dev/pdufa/tislelizumab) | ONC |  | completed, approved | "On March 4, 2025, we announced the U.S. Food and Drug Administration has approved TEVIMBRA (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 (≥1)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1651308/000165130825000075/bgne-20250331.htm)) |
| April 22, 2025 | [Tevimbra (tislelizumab-jsgr) label expansion decision](https://sec-api.dev/pdufa/tislelizumab-jsgr) | ONC |  | completed, approved | "BLA761232 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20250422, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22)) |
| May 7, 2025 | [BeOne Medicines Ltd. earnings report](https://sec-api.dev/companies/onc/catalysts) | ONC |  | completed | "BeiGene Announces First Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000165130825000074/exhibit991-q12025earningsr.htm)) |
| May 30, 2025 | [TEVIMBRA® (tislelizumab) primary completion](https://sec-api.dev/pdufa/tislelizumab) | ONC | Non-small Cell Lung Cancer; NSCLC | withdrawn | "NCT04746924 (A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor BeiGene; Results First Posted 2026-05-12." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04746924)) |
| May 30, 2025 | [Alcestobart primary completion](https://sec-api.dev/pdufa/alcestobart) | ONC |  | completed | "NCT06010303 (A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-30 (ACTUAL); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06010303)) |
| June 10, 2025 | [BRUKINSA® (zanubrutinib) FDA approval](https://sec-api.dev/pdufa/zanubrutinib) | ONC |  | completed, approved | "NDA218785 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20250610, review_priority STANDARD; sponsor_name BEONE MEDICINES USA; product BRUKINSA (ZANUBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218785%22)) |
| June 17, 2025 | [Alcestobart primary completion](https://sec-api.dev/pdufa/alcestobart) | ONC | Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer | completed | "NCT05909904 (A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-17 (ACTUAL); Lead Sponsor BeiGene; Results First Posted 2026-07-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05909904)) |
| 2H 2025 | [TIG-302 interim data readout](https://sec-api.dev/pdufa/tig-302) | ONC |  | scheduled | "•Advan-TIG-302 (TIGIT antibody): anticipate interim data readout from Phase 3 study in first-line PD(L)1-high non small cell lung cancer in the second half of 2025;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000165130825000029/exhibit991-q42024earningsr.htm)) |
| 2H 2025 | [Jaypirca (pirtobrutinib) trial start](https://sec-api.dev/pdufa/pirtobrutinib) | ONC |  | scheduled | "•Anticipate initiation of Phase 3 head-to-head trial against noncovalent BTK inhibitor pirtobrutinib in R/R CLL in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000165130825000029/exhibit991-q42024earningsr.htm)) |
| August 6, 2025 | [BeOne Medicines Ltd. earnings report](https://sec-api.dev/companies/onc/catalysts) | ONC |  | completed | "BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000165130825000131/exhibit991-q22025earningsr.htm)) |
| August 29, 2025 | [BEQALZI™ (sonrotoclax) topline data readout](https://sec-api.dev/pdufa/sonrotoclax) | ONC | relapsed/refractory mantle cell lymphoma | completed, positive | "On August 29, 2025, we announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory mantle cell lymphoma, following treatment with a Bruton's tyrosine kinase inhibitor ("BTKi") and anti-CD20 therapy." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1651308/000162828025049824/bgne-20250930.htm)) |
| October 13, 2025 | [TEVIMBRA® (tislelizumab) primary completion](https://sec-api.dev/pdufa/tislelizumab) | ONC | Classical Hodgkin Lymphoma | withdrawn | "NCT04486391 (Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04486391)) |
| November 6, 2025 | [BeOne Medicines Ltd. earnings report](https://sec-api.dev/companies/onc/catalysts) | ONC |  | completed | "BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000162828025049821/exhibit991-q32025earningsr.htm)) |
| November 26, 2025 | [BEQALZI™ (sonrotoclax) NDA/BLA acceptance](https://sec-api.dev/pdufa/sonrotoclax) | ONC |  | completed | "On November 26, 2025, we announced that the U.S. Food and Drug Administration ("FDA") accepted and granted Priority Review to a New Drug Application ("NDA") for sonrotoclax for the treatment of adult patients with R/R MCL, following treatment with a Bruton's tyrosine kinase ("BTK") inhibitor." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1651308/000162828026011946/bgne-20251231.htm)) |
| December 1, 2025 | [Pamiparib capsule primary completion](https://sec-api.dev/pdufa/pamiparib) | ONC | Ovarian Cancer | completed | "NCT03519230 (Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-12-01 (ACTUAL); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03519230)) |
| December 9, 2025 | [Tevimbra (tislelizumab-jsgr) label expansion decision](https://sec-api.dev/pdufa/tislelizumab-jsgr) | ONC |  | completed, approved | "BLA761232 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20251209, review_priority STANDARD; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22)) |
| December 19, 2025 | [LBL-007 primary completion](https://sec-api.dev/pdufa/lbl-007) | ONC | Non-small Cell Lung Cancer; Metastatic Non-small Cell Lung Cancer | completed | "NCT05635708 (A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-19 (ACTUAL); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05635708)) |
| 2026 | [Tacabrutideg topline data readout](https://sec-api.dev/pdufa/tacabrutideg) | ONC | R/R CLL with data readout | scheduled | "•BGB-16673 (BTK CDAC): Continued enrollment of potentially registration enabling Phase 2 trial for the treatment of R/R CLL with data readout expected in 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000165130825000074/exhibit991-q12025earningsr.htm)) |
| January 9, 2026 | [BRUKINSA® (zanubrutinib) primary completion](https://sec-api.dev/pdufa/zanubrutinib) | ONC |  | completed | "NCT04116437 (Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-01-09 (ACTUAL); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04116437)) |
| February 26, 2026 | [BRUKINSA® (zanubrutinib) earnings report](https://sec-api.dev/pdufa/zanubrutinib) | ONC |  | completed | "BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000162828026011941/exhibit991-q42025earningsr.htm)) |
| April 27, 2026 | [BRUKINSA® (zanubrutinib) primary completion](https://sec-api.dev/pdufa/zanubrutinib) | ONC | Mantle Cell Lymphoma; Non-Hodgkin Lymphoma | completed | "NCT04002297 (A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-27 (ACTUAL); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04002297)) |
| May 6, 2026 | [BeOne Medicines Ltd. earnings report](https://sec-api.dev/companies/onc/catalysts) | ONC |  | completed | "BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000162828026030866/exhibit991-q12026earningsr.htm)) |
| May 12, 2026 | [BGB-45035 primary completion](https://sec-api.dev/pdufa/bgb-45035) | ONC | Rheumatoid Arthritis | withdrawn | "NCT07100938 (A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-05-12 (ACTUAL); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07100938)) |
| May 13, 2026 | [BEQALZI™ (sonrotoclax) FDA approval](https://sec-api.dev/pdufa/sonrotoclax) | ONC |  | completed, approved | "Beqalzi \| sonrotoclax \| 5/13/2026 \| To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase inhibitor" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| May 23, 2026 | [BAT1706 primary completion](https://sec-api.dev/pdufa/bat1706) | ONC | Advanced Malignancies | completed | "NCT04164199 (Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-05-23 (ACTUAL); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04164199)) |
| June 30, 2026 | [BRUKINSA® (zanubrutinib) topline data readout](https://sec-api.dev/pdufa/zanubrutinib) | ONC | previously untreated mantle cell lymphoma | completed, positive | "On June 30, 2026, we announced positive topline results from the Phase 3 MANGROVE study (BGB-3111-306) evaluating foundational Bruton's tyrosine kinase ("BTK") inhibitor BRUKINSA® plus rituximab versus bendamustine plus rituximab in adult patients with previously untreated mantle cell lymphoma ("MCL")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1651308/000162828026052878/bgne-20260630.htm)) |
| July 14, 2026 | [Alcestobart topline data readout](https://sec-api.dev/pdufa/alcestobart) | ONC | Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer | completed | "NCT05909904 (A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-17 (ACTUAL); Lead Sponsor BeiGene; Results First Posted 2026-07-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05909904?tab=results)) |
| August 5, 2026 | [BeOne Medicines Ltd. earnings report](https://sec-api.dev/companies/onc/catalysts) | ONC |  | completed | "BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000162828026052877/exhibit991-q22026earningsr.htm)) |
| August 25, 2026 | [TEVIMBRA® (tislelizumab) label expansion decision](https://sec-api.dev/pdufa/tislelizumab) | ONC |  | completed, approved | "On August 25, 2026, we announced that the U.S. Food and Drug Administration ("FDA") approved the supplemental Biologics License Application ("sBLA") for TEVIMBRA in combination with ZIIHERA and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2+ gastric, gastroesophageal junction, or GEA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1651308/000162828026070477/bgne-20260930.htm)) |
| August 25, 2026 | [Tevimbra (tislelizumab-jsgr) label expansion decision](https://sec-api.dev/pdufa/tislelizumab-jsgr) | ONC |  | completed, approved | "BLA761232 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20260825, review_priority PRIORITY; sponsor_name BEIGENE; product TEVIMBRA (TISLELIZUMAB-JSGR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761232%22)) |
| August 31, 2026 | [GEA-01 topline data readout](https://sec-api.dev/pdufa/gea-01) | ONC |  | completed, positive | "On August 31, 2026, we announced positive topline results from the second interim analysis of the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), in combination with chemotherapy, with and without TEVIMBRA® (tislelizumab), as first-line treatment for HER2-positive ("HER2+") locally advanced or metastatic gastroesophageal adenocarcinoma ("GEA")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1651308/000162828026070477/bgne-20260930.htm)) |
| September 22, 2026 | [BEQALZI™ (sonrotoclax) primary completion](https://sec-api.dev/pdufa/sonrotoclax) | ONC |  | completed | "NCT05952037 (A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05952037)) |
| Sep to Dec 2026 | [BEQALZI™ (sonrotoclax) topline data readout](https://sec-api.dev/pdufa/sonrotoclax) | ONC |  | scheduled | "NCT05952037 (A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05952037)) |
| November 2026 | [Tislelizumab (bgb-a317) primary completion](https://sec-api.dev/pdufa/tislelizumab-bgb-a317) | ONC | MSI-H/dMMR Solid Tumors | scheduled | "NCT03736889 (Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03736889)) |
| Nov 2026 to Feb 2027 | [Tislelizumab (bgb-a317) topline data readout](https://sec-api.dev/pdufa/tislelizumab-bgb-a317) | ONC | MSI-H/dMMR Solid Tumors | scheduled | "NCT03736889 (Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03736889)) |
| November 2026 | [BEQALZI™ (sonrotoclax) primary completion](https://sec-api.dev/pdufa/sonrotoclax) | ONC | Chronic Lymphocytic Leukemia | scheduled | "NCT06637501 (A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06637501)) |
| Nov 2026 to Feb 2027 | [BEQALZI™ (sonrotoclax) topline data readout](https://sec-api.dev/pdufa/sonrotoclax) | ONC | Chronic Lymphocytic Leukemia | scheduled | "NCT06637501 (A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06637501)) |
| November 5, 2026 | [BeOne Medicines Ltd. earnings report](https://sec-api.dev/companies/onc/catalysts) | ONC |  | completed | "BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1651308/000162828026070469/exhibit991-q32026earningsr.htm)) |
| Dec 2026 to Mar 2027 | [BRUKINSA® (zanubrutinib) topline data readout](https://sec-api.dev/pdufa/zanubrutinib) | ONC | B-cell Malignancies | scheduled | "NCT04170283 (A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04170283)) |
| December 2026 | [BRUKINSA® (zanubrutinib) primary completion](https://sec-api.dev/pdufa/zanubrutinib) | ONC | B-cell Malignancies | scheduled | "NCT04170283 (A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04170283)) |
| Jun to Sep 2027 | [TEVIMBRA® (tislelizumab) topline data readout](https://sec-api.dev/pdufa/tislelizumab) | ONC | Urothelial Carcinoma | scheduled | "NCT03967977 (Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03967977)) |
| June 2027 | [TEVIMBRA® (tislelizumab) primary completion](https://sec-api.dev/pdufa/tislelizumab) | ONC | Urothelial Carcinoma | scheduled | "NCT03967977 (Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor BeiGene." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03967977)) |
| October 2027 | [BRUKINSA® (zanubrutinib) primary completion](https://sec-api.dev/pdufa/zanubrutinib) | ONC | Primary Membranous Nephropathy | scheduled | "NCT05707377 (A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05707377)) |
| Oct 2027 to Jan 2028 | [BRUKINSA® (zanubrutinib) topline data readout](https://sec-api.dev/pdufa/zanubrutinib) | ONC | Primary Membranous Nephropathy | scheduled | "NCT05707377 (A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05707377)) |
| Oct 2027 to Jan 2028 | [Subcutaneous tislelizumab topline data readout](https://sec-api.dev/pdufa/subcutaneous-tislelizumab) | ONC | Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | scheduled | "NCT07043400 (A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-30 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07043400)) |
| October 2027 | [Subcutaneous tislelizumab primary completion](https://sec-api.dev/pdufa/subcutaneous-tislelizumab) | ONC | Metastatic Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma | scheduled | "NCT07043400 (A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-30 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07043400)) |
| Feb to May 2028 | [TEVIMBRA® (tislelizumab) topline data readout](https://sec-api.dev/pdufa/tislelizumab) | ONC | Advanced Esophageal Squamous Cell Carcinoma; Metastatic Esophageal Squamous Cell Carcinoma | scheduled | "NCT07733180 (A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07733180)) |
| February 2028 | [TEVIMBRA® (tislelizumab) primary completion](https://sec-api.dev/pdufa/tislelizumab) | ONC | Advanced Esophageal Squamous Cell Carcinoma; Metastatic Esophageal Squamous Cell Carcinoma | scheduled | "NCT07733180 (A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07733180)) |
| Mar to Jun 2028 | [Bgb-b2033 topline data readout](https://sec-api.dev/pdufa/bgb-b2033) | ONC | Hepatocellular Cancer; Liver Cancer; Hepatocellular Carcinoma | scheduled | "NCT07911683 (Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07911683)) |
| March 2028 | [Bgb-b2033 primary completion](https://sec-api.dev/pdufa/bgb-b2033) | ONC | Hepatocellular Cancer; Liver Cancer; Hepatocellular Carcinoma | scheduled | "NCT07911683 (Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07911683)) |
| Apr to Jul 2028 | [Tacabrutideg topline data readout](https://sec-api.dev/pdufa/tacabrutideg) | ONC | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT06973187 (A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-17 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06973187)) |
| April 2028 | [Tacabrutideg primary completion](https://sec-api.dev/pdufa/tacabrutideg) | ONC | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT06973187 (A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-17 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06973187)) |
| May to Aug 2028 | [Tacabrutideg topline data readout](https://sec-api.dev/pdufa/tacabrutideg) | ONC | CLL; Chronic Lymphocytic Leukemia; SLL | scheduled | "NCT06846671 (A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-15 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06846671)) |
| May 2028 | [Tacabrutideg primary completion](https://sec-api.dev/pdufa/tacabrutideg) | ONC | CLL; Chronic Lymphocytic Leukemia; SLL | scheduled | "NCT06846671 (A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-15 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06846671)) |
| July 2028 | [BRUKINSA® (zanubrutinib) primary completion](https://sec-api.dev/pdufa/zanubrutinib) | ONC | Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma | scheduled | "NCT05100862 (A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05100862)) |
| Jul to Oct 2028 | [BRUKINSA® (zanubrutinib) topline data readout](https://sec-api.dev/pdufa/zanubrutinib) | ONC | Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma | scheduled | "NCT05100862 (A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05100862)) |
| Aug to Nov 2028 | [BEQALZI™ (sonrotoclax) topline data readout](https://sec-api.dev/pdufa/sonrotoclax) | ONC | Mantle Cell Lymphoma; B Cell Lymphoma | scheduled | "NCT06742996 (A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-31 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06742996)) |
| August 2028 | [BEQALZI™ (sonrotoclax) primary completion](https://sec-api.dev/pdufa/sonrotoclax) | ONC | Mantle Cell Lymphoma; B Cell Lymphoma | scheduled | "NCT06742996 (A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-31 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06742996)) |
| April 2029 | [BGB-43395 primary completion](https://sec-api.dev/pdufa/bgb-43395) | ONC | HR+/HER2- Breast Cancer | scheduled | "NCT07492641 (BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07492641)) |
| Apr to Jul 2029 | [BGB-43395 topline data readout](https://sec-api.dev/pdufa/bgb-43395) | ONC | HR+/HER2- Breast Cancer | scheduled | "NCT07492641 (BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07492641)) |
| Sep to Dec 2029 | [BEQALZI™ (sonrotoclax) topline data readout](https://sec-api.dev/pdufa/sonrotoclax) | ONC | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT06943872 (A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-30 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06943872)) |
| Sep to Dec 2029 | [Bgb-b2033 topline data readout](https://sec-api.dev/pdufa/bgb-b2033) | ONC | Hepatocellular Carcinoma; Liver Cancer | scheduled | "NCT07836530 (Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-21 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07836530)) |
| September 2029 | [Bgb-b2033 primary completion](https://sec-api.dev/pdufa/bgb-b2033) | ONC | Hepatocellular Carcinoma; Liver Cancer | scheduled | "NCT07836530 (Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Advanced Hepatocellular Carcinoma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-21 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07836530)) |
| September 2029 | [BEQALZI™ (sonrotoclax) primary completion](https://sec-api.dev/pdufa/sonrotoclax) | ONC | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT06943872 (A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-09-30 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06943872)) |
| Nov 2029 to Feb 2030 | [Tacabrutideg topline data readout](https://sec-api.dev/pdufa/tacabrutideg) | ONC | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT06970743 (A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-11-30 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06970743)) |
| Nov 2029 to Feb 2030 | [Bg-c9074 topline data readout](https://sec-api.dev/pdufa/bg-c9074) | ONC | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | scheduled | "NCT07811271 (Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-11-30 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07811271)) |
| November 2029 | [Tacabrutideg primary completion](https://sec-api.dev/pdufa/tacabrutideg) | ONC | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT06970743 (A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-11-30 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06970743)) |
| November 2029 | [Bg-c9074 primary completion](https://sec-api.dev/pdufa/bg-c9074) | ONC | Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | scheduled | "NCT07811271 (Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal Cancers): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-11-30 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07811271)) |

## Drugs

- [Alcestobart](https://sec-api.dev/pdufa/alcestobart): Esophageal Cancer, Head and Neck Squamous Cell Carcinoma
- [BAT1706](https://sec-api.dev/pdufa/bat1706): Advanced Malignancies
- [Bg-c9074](https://sec-api.dev/pdufa/bg-c9074): Epithelial Ovarian Cancer
- [BGB-43395](https://sec-api.dev/pdufa/bgb-43395): HR+/HER2- Breast Cancer
- [BGB-45035](https://sec-api.dev/pdufa/bgb-45035): Rheumatoid Arthritis
- [Bgb-b2033](https://sec-api.dev/pdufa/bgb-b2033): Hepatocellular Cancer, Hepatocellular Carcinoma
- [LBL-007](https://sec-api.dev/pdufa/lbl-007): Non-small Cell Lung Cancer
- [Pamiparib capsule](https://sec-api.dev/pdufa/pamiparib): Ovarian Cancer
- [BEQALZI™ (sonrotoclax)](https://sec-api.dev/pdufa/sonrotoclax): relapsed/refractory mantle cell lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
- [Subcutaneous tislelizumab](https://sec-api.dev/pdufa/subcutaneous-tislelizumab): Metastatic Gastric Adenocarcinoma
- [Tacabrutideg](https://sec-api.dev/pdufa/tacabrutideg): r/r cll with data readout, Chronic Lymphocytic Leukemia, CLL
- [TIG-302](https://sec-api.dev/pdufa/tig-302): 
- [TEVIMBRA® (tislelizumab)](https://sec-api.dev/pdufa/tislelizumab): Advanced Esophageal Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Urothelial Carcinoma, Classical Hodgkin Lymphoma
- [Tislelizumab (bgb-a317)](https://sec-api.dev/pdufa/tislelizumab-bgb-a317): MSI-H/dMMR Solid Tumors
- [Tevimbra (tislelizumab-jsgr)](https://sec-api.dev/pdufa/tislelizumab-jsgr): To treat unresectable or metastatic esophageal squamous cell carcinoma, same proposed indication
- [BRUKINSA® (zanubrutinib)](https://sec-api.dev/pdufa/zanubrutinib): previously untreated mantle cell lymphoma, B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Relapsed/Refractory Follicular Lymphoma, Mantle Cell Lymphoma; Non-Hodgkin Lymphoma, Primary Membranous Nephropathy

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/onc/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ONC catalysts: BeOne Medicines Ltd. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/onc/catalysts

```bibtex
@misc{secapidev_companies_onc_catalysts_20261116,
  title        = {ONC catalysts: BeOne Medicines Ltd. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/onc/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_onc_catalysts_20261116","title":"ONC catalysts: BeOne Medicines Ltd. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/onc/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
